Hexbyte Tech News Wired
In the early 2000s, a handful of young scientists at Stanford turned the university’s Palo Alto campus into the mouse-stitching-together capital of the world. Reviving a centuries-old procedure known as parabiosis, they connected the circulatory systems of dozens of pairs of rodents, young sutured to old, so that they’d pump one another’s blood back and forth. The grisly experiments rejuvenated the aging mice, making them stronger and healthier, and introducing the 21st century’s longevity enthusiasts to the therapeutic potential of young blood.
While much work remains to be done on how this regenerative process actually works, Stanford’s parabiosis studies have since inspired the creation of a handful of ambitious startups aimed at producing similarly dramatic effects in humans. Today, the latest young-blood medicine-maker, Elevian, emerged from stealth with $5.5 million from investors including Peter Diamandis, one of the more prominent faces in the Silicon Valley “death disruption” scene.